Core Viewpoint - Veracyte, Inc. has appointed Kevin Haas, Ph.D., as Chief Development and Technology Officer to enhance its global product development strategy in cancer diagnostics [1][3] Group 1: Leadership Appointment - Kevin Haas will join Veracyte on March 24, 2026, in a newly created role focused on overseeing end-to-end product development, including diagnostic assay development, software, and bioinformatics [1][2] - Dr. Haas has over 15 years of experience in the life sciences industry, previously serving as Chief Technology Officer at Myriad Genetics, where he led the development of precision medicine platforms [3][4] Group 2: Product Development Strategy - The expansion of Veracyte's pipeline into whole-genome minimal residual disease (MRD) and multiomics applications necessitates integrated capabilities across assays, software, AI, and next-generation informatics [2] - Dr. Haas will lead efforts to deliver high-quality laboratory-developed tests (LDTs) and global in vitro diagnostic (IVD) products, aiming to accelerate innovation and support the company's global portfolio [2][3] Group 3: Company Vision and Goals - Veracyte aims to transform cancer care by providing clinicians with high-value insights for diagnosing and treating cancer, supported by a robust diagnostics platform [5][6] - The company emphasizes the importance of genomic and clinical data, bioinformatics, and AI capabilities in driving innovation and pipeline development [5][6]

Summary of Veracyte's Conference Call Company Overview - **Company**: Veracyte - **Industry**: Molecular diagnostics, specifically focused on cancer diagnostics - **Mission**: Enhance understanding of cancer and improve treatment through advanced molecular diagnostics, aiming to reach patients globally [2][3] Core Business and Financial Performance - **Revenue**: Achieved $517 million in 2025, with an 18% growth in testing revenue [5] - **Adjusted EBITDA Margin**: Exceeded 27% in 2025, surpassing the 25% target set for the year [6][26] - **Patient Reach**: Over 800,000 patients served to date, with expectations to serve the 1 millionth patient in 2026 [6][28] - **Growth Drivers**: Core business growth from Decipher and Afirma expected to support double-digit revenue growth in the foreseeable future [18] Product Portfolio Decipher Test - **Focus**: Prostate cancer prognosis and prediction, providing genomic insights to guide treatment decisions [7] - **Market Penetration**: Estimated at 33% as of the end of 2025, with significant growth potential [9] - **Volume Growth**: Achieved over 20% volume growth for 15 consecutive quarters, with a 3-year revenue CAGR of over 37% [9][10] - **Clinical Evidence**: Supported by over 100 publications, recognized in NCCN guidelines [10] Afirma Test - **Focus**: Thyroid nodule diagnosis, helping patients avoid unnecessary surgeries [15] - **Market Penetration**: Currently 38% penetrated into the Bethesda III to VI category [15] - **Volume Growth**: Experienced 11% volume growth in 2025, driven by new account wins and increased utilization [16] Upcoming Products - **TrueMRD**: Launching in 2026 for muscle invasive bladder cancer, leveraging the Decipher brand [18][22] - **Prosigna**: Expected launch in mid-2026, targeting breast cancer patients with significant market opportunity [19][20] Strategic Initiatives - **Data-Driven Approach**: Emphasizes generating more data to enhance clinical utility and adoption of tests [3][21] - **Digital Pathology and AI**: Exploring integration with molecular diagnostics, focusing on generating robust clinical evidence before commercialization [39] - **Geographic Expansion**: Plans to introduce tests like Prosigna and Decipher in Europe, addressing significant patient populations [23][24] Market Challenges and Opportunities - **Prostate Cancer**: Approximately 334,000 patients diagnosed annually in the U.S., with a growing clinical challenge [8] - **Bladder Cancer**: Strong momentum with Decipher Bladder, integrating research to guide future treatment [10][11] - **Lung Cancer**: Developing Percepta nasal swab to address early risk stratification in lung cancer patients [25] Key Takeaways - **Durability of Growth**: Confidence in sustaining growth in core business and pipeline products [40] - **Financial Strength**: Unique financial profile with strong cash generation and profitability [41] - **Underappreciated Aspects**: Core business growth, pipeline potential, and financial stability are key areas that may not be fully recognized by investors [41]

Core Insights - Veracyte, Inc. (VCYT) reported fourth-quarter 2025 adjusted earnings of 53 cents per share, a 47.2% increase year-over-year, exceeding the Zacks Consensus Estimate by 30.06% [1] - The company's GAAP earnings per share were 52 cents, compared to 7 cents in the same period last year [1] - For the full year 2025, EPS reached $1.78, marking a 49.6% increase from the previous year and surpassing estimates by 6.2% [1] Revenue Performance - Revenues for Q4 2025 increased by 18.5% year-over-year to $140.6 million, beating the Zacks Consensus Estimate by 1.4% [2] - Total revenues for 2025 were reported at $517.1 million, a 16% increase from the prior year, also surpassing estimates by 0.4% [2] - Following the earnings announcement, VCYT shares rose by 1.9% in after-hours trading [2] Segmental Revenue Breakdown - Testing revenues reached $135.8 million, up 21.1% year-over-year, driven by growth in Decipher and Afirma revenues of 27% and 16%, respectively [3] - Total testing volume was approximately 45,500, reflecting a 16% increase compared to the prior year [3] - Product revenues increased by 27% year-over-year to $3 million in Q4 [3] Margin Analysis - Total cost of revenues was $36 million, a decrease of 3% year-over-year [5] - Gross profit rose by 28.3% to $104.7 million, with gross margin expanding by 568 basis points to 74.4% [5] - Selling and marketing expenses increased by 4.5% to $25.9 million, while general and administrative expenses decreased by 35.5% to $17 million [5] Cash and Capital Structure - Veracyte ended Q4 2025 with cash and cash equivalents of $362.6 million, up from $239.1 million at the end of 2024 [6] - Cumulative net cash from operating activities was $136.3 million, compared to $75.1 million a year ago [6] Future Guidance - The company reiterated its 2026 revenue guidance of $570 million to $582 million, indicating a growth of 10-13%, with testing revenues expected to grow by 14-16% [8] - The adjusted EBITDA margin is projected to be 25% for 2026 [8] Overall Performance Assessment - Veracyte's fourth-quarter performance showed earnings and revenues exceeding estimates, supported by strong growth in the core testing business [9] - The company has seen a steady pipeline of account wins in Affirma and increased utilization per account, continuing into Q4 [9] - The transition of all Afirma volume to a more scalable, lower-cost platform and record growth in Decipher orders are positive indicators for future performance [10]

Core Insights - Veracyte, Inc. is a leading company in the cancer diagnostics field, specializing in advanced genomic tests for cancer diagnosis and treatment, with notable product lines like Decipher and Afirma [1] Financial Performance - On February 25, 2026, Veracyte reported an earnings per share (EPS) of $0.50, exceeding the estimated EPS of $0.40, indicating effective management and higher profit generation [2][6] - The company's revenue reached approximately $140.6 million, surpassing the anticipated $135.8 million, highlighting the growth of its Decipher and Afirma product lines [2][6] Market Position and Growth - In the last quarter of 2025, Veracyte served over 45,000 patients with its core testing services, demonstrating its ability to expand market presence and deliver valuable diagnostic solutions [3] - The company has a price-to-earnings (P/E) ratio of approximately 42.62, reflecting market confidence in its earnings potential [4] Financial Health - Veracyte has a low debt-to-equity ratio of 0.03, indicating minimal reliance on debt financing, and a strong current ratio of 8.15, suggesting robust liquidity [5] - The enterprise value to sales ratio is around 4.84, and the enterprise value to operating cash flow ratio is approximately 18.35, providing a comprehensive view of its valuation relative to sales and cash flow [4]

Financial Data and Key Metrics Changes - Fourth quarter total revenue was $141 million, representing a 19% year-over-year growth, driven by a 21% growth in the core testing business [5][25] - Full year total revenue reached $517 million, achieving 16% growth, with nearly 170,000 patients provided clinically actionable information [6][28] - Adjusted EBITDA margin exceeded 27% in 2025, surpassing the 25% target more than a year ahead of plan [7][28] Business Line Data and Key Metrics Changes - Decipher volume grew 21% in Q4, while Afirma grew 12%, contributing to a total testing volume growth of 16% [5][25] - Testing revenue during Q4 was $135.8 million, an increase of 21% year-over-year, with Decipher and Afirma revenue growth of 27% and 16%, respectively [25][26] - Approximately 18,250 Afirma tests were delivered in Q4, representing 12% volume growth, while Decipher tests reached approximately 27,200, marking 15 consecutive quarters of over 20% year-over-year volume growth [9][11] Market Data and Key Metrics Changes - Decipher is recognized as the only gene expression test with high-quality evidence in NCCN guidelines, contributing to its growth [12] - The market penetration for Decipher is approximately 33%, indicating significant room for growth as two-thirds of patients are still not utilizing the test [12][52] - The bladder cancer segment is currently a small portion of Decipher's total volume, but there is potential for increased use as clinical evidence develops [80] Company Strategy and Development Direction - The company plans to launch two major products in 2026: TruMRD for muscle-invasive bladder cancer and Prosigna for early-stage breast cancer [8][21] - A phased expansion strategy is in place, focusing on core business momentum and new product launches [8][24] - The company aims to sustain double-digit growth through its portfolio of tests in prostate, thyroid, bladder, and breast cancer [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining double-digit revenue growth, supported by a strong pipeline and operational efficiencies [7][24] - The company is focused on building clinical evidence and expanding its market presence, particularly in advanced disease settings [15][19] - Management highlighted the importance of investing in growth drivers while maintaining profitability [28][46] Other Important Information - The company completed the transition of Afirma to a more scalable, lower-cost v2 transcriptome platform, improving operational efficiency [7][10] - The company has a strong cash position, ending the quarter with $412.9 million in cash and cash equivalents, providing flexibility for future investments [25][28] Q&A Session Summary Question: Guidance and Assumptions for 2026 - Management reiterated strong conviction in the 2026 guidance, with factors influencing the high and low ends of the range discussed [32][34] Question: Market Expansion for Prosigna - The potential market for Prosigna is significant, with 225,000 patients annually expected to be addressed by the indication [40] Question: Competitive Dynamics in Decipher Market - Management noted no significant changes in competitive dynamics, with Decipher continuing to show strong growth supported by clinical evidence [52][54] Question: Capital Allocation Strategy - The company maintains a deliberate approach to capital allocation, focusing on organic growth and infrastructure development [69][70]

Financial Data and Key Metrics Changes - Fourth quarter total revenue was $141 million, representing a 19% year-over-year growth, driven by a 21% growth in the core testing business [5][25] - Full year total revenue reached $517 million, achieving 16% growth, with nearly 170,000 patients provided clinically actionable information [6][28] - Adjusted EBITDA margin exceeded 27% in 2025, surpassing the 25% target more than a year ahead of plan [7][28] Business Line Data and Key Metrics Changes - Decipher volume grew 21% in Q4, with approximately 27,200 tests delivered, marking the 15th consecutive quarter of over 20% year-over-year volume growth [11][12] - Afirma delivered approximately 18,250 tests in Q4, representing a 12% volume growth, with a market share of approximately 38% [9][10] - Total testing volume for the quarter was approximately 48,000 tests, a 16% increase over the same period in 2024 [25] Market Data and Key Metrics Changes - Decipher is recognized as the only gene expression test with high-quality evidence in NCCN guidelines, contributing to its growth [12] - The bladder cancer market is transitioning towards more biologically informed evaluations, with Decipher Bladder gaining traction [18][80] - The prostate cancer market penetration for Decipher is approximately 33%, indicating significant room for growth [12][52] Company Strategy and Development Direction - The company plans to launch two major products in 2026: TruMRD for muscle-invasive bladder cancer and Prosigna for early-stage breast cancer [8][21] - A phased expansion strategy is in place, focusing on core business momentum and new product launches [8][24] - The company aims to sustain double-digit growth through its portfolio of tests in prostate, thyroid, bladder, and breast cancer [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining double-digit growth, supported by a strong financial profile and ongoing investments in growth drivers [28][30] - The company is optimistic about the upcoming product launches and their potential to drive revenue growth [23][30] - Management highlighted the importance of generating clinical evidence to support product adoption and market penetration [16][47] Other Important Information - The company completed the transition of Afirma to a more scalable, lower-cost v2 transcriptome platform, improving operational efficiency [7][10] - The company has a strong cash position, ending the quarter with $412.9 million in cash and cash equivalents [25][28] Q&A Session Summary Question: Has the conviction in the guidance evolved in any way? - Management reiterated strong conviction in the guidance, with expectations for seasonal trends impacting Q1 performance [32][34] Question: What readout is required for the OPTIMA study to expand the intended use population? - Management indicated that the OPTIMA study includes patients with up to nine nodes, and the results will determine future market expansion [40][41] Question: Can you discuss the competitive dynamics for Decipher? - Management noted that Decipher continues to grow despite competition, with strong evidence supporting its market position [52][54]

Financial Data and Key Metrics Changes - Fourth quarter total revenue was $141 million, representing a 19% year-over-year growth driven by a strong core testing business which grew 21% [4] - Full year total revenue reached $517 million, achieving 16% growth [5] - Adjusted EBITDA margin exceeded 27% in 2025, surpassing the 25% target more than a year ahead of plan [6][29] - Cash from operations for Q4 was $52.6 million, ending the quarter with $412.9 million in cash and cash equivalents [26] Business Line Data and Key Metrics Changes - Decipher volume grew 21% in Q4, with approximately 27,200 tests delivered, marking the 15th consecutive quarter of over 20% year-over-year volume growth [11] - Afirma delivered approximately 18,250 tests in Q4, representing 12% volume growth [9] - Total testing volume for Q4 was approximately 48,000 tests, a 16% increase over the same period in 2024 [26] Market Data and Key Metrics Changes - Decipher is recognized as the only gene expression test with high-quality evidence in NCCN guidelines, contributing to its growth [12] - The market penetration for Decipher is approximately 33%, indicating significant room for growth as two-thirds of patients are not yet utilizing the test [53] - The bladder cancer market is transitioning towards more biologically informed evaluations, with Decipher Bladder being integrated into studies to guide treatment decisions [17][85] Company Strategy and Development Direction - The company plans to launch two new products in 2026: TruMRD for muscle-invasive bladder cancer and Prosigna for early-stage breast cancer [8][21] - A phased expansion strategy is in place, focusing on core business momentum and new product launches [7] - The company aims to sustain double-digit growth through its portfolio of tests across prostate, thyroid, bladder, and breast cancer [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining double-digit growth, supported by a strong pipeline and ongoing clinical evidence generation [25][32] - The company is prepared to invest in growth drivers while maintaining profitability, with a focus on clinical evidence and product launches [46][49] - Management highlighted the importance of navigating evolving market dynamics and maintaining a strong operational model [24] Other Important Information - The company achieved significant milestones in 2025, including the launch of Decipher for metastatic patients and the transition of Afirma to a more scalable platform [5][6] - The company is on track to test its 1 millionth patient later this year, reflecting the scale and impact of its platform [5] Q&A Session Summary Question: Has your conviction in the guidance evolved in any way? - Management reiterated strong conviction in guidance, noting seasonal trends and potential drivers for high and low ends of the range [34][35] Question: What readout is required for the OPTIMA study to expand the intended use population? - Management indicated that the OPTIMA study includes enrollment criteria that could allow for expansion, pending positive results [40][42] Question: Can you walk through the push and pulls regarding the margin guidance for 2026? - Management explained that the guidance reflects the need for flexibility to invest in new product launches while maintaining profitability [45][49] Question: How is the competitive landscape for Decipher evolving? - Management noted that Decipher continues to grow despite competition, with strong evidence supporting its use in clinical guidelines [53][55] Question: What is the expected volume growth for Afirma and Decipher in 2026? - Management indicated that Afirma is expected to grow in the mid to high single digits, while Decipher is projected to grow approximately 20% [30][90]

Core Insights - Veracyte, Inc. is expected to report quarterly earnings on February 25, 2026, with an anticipated EPS of $0.41 and revenue of approximately $135.8 million, driven by its genomic diagnostics tests, Decipher and Afirma [1][5] Financial Performance - In the previous quarter, Veracyte's adjusted EPS was $0.51, exceeding the Zacks Consensus Estimate by 59.38%, and the company has consistently surpassed earnings estimates over the last four quarters with an average surprise of 45.12% [2] - The upcoming Q4 EPS estimate reflects a 13.9% increase from the previous year, with earnings estimates revised upwards by 2% ahead of the announcement [2] Valuation Metrics - Veracyte's financial metrics indicate a high valuation, with a P/E ratio of approximately 94.73, suggesting investors are willing to pay a premium for its earnings [3][5] - The price-to-sales ratio is about 5.82, indicating that investors are paying over five times the company's sales per share [3] - The enterprise value to sales ratio is around 5.27, and the enterprise value to operating cash flow ratio is approximately 24.10 [3] Financial Health - The company's earnings yield is about 1.06%, and it maintains a low debt-to-equity ratio of 0.03, indicating minimal reliance on debt financing [4] - Veracyte has a strong current ratio of 6.23, suggesting robust liquidity and the ability to cover short-term liabilities [4]

Core Insights - Brown Capital Management's Small Company Fund underperformed in Q4 2025, with a decline of 1.50% compared to the Russell 2000® Growth index's gain of 1.22% [1] - The Fund's performance for the entire year of 2025 was down 11.46%, significantly lagging behind the Index's return of 13.01% [1] - The Fund's investment strategy is focused on company fundamentals, which showed strong revenue and earnings growth in 2025 [1] Company Focus: Veracyte, Inc. - Veracyte, Inc. is highlighted as a key holding in the Fund, with a market capitalization of $2.817 billion [2] - The stock price of Veracyte, Inc. closed at $35.63 on February 20, 2026, with a one-month return of -12.18% and a 52-week loss of 9.48% [2] - Veracyte holds a dominant market position with over 50% market share in its core products, Decipher and Afirma, which contributed more than 90% of revenue in 2024 [3] - The Decipher product has a market penetration of only 40%, indicating potential for double-digit growth in the coming years, while Afirma offers stability due to higher market penetration [3] - Veracyte's product pipeline could expand its market opportunity by over $3 billion, including tests for breast cancer, prostate cancer, and lung cancer [3] - The company turned profitable in 2024 and has shown significant margin expansion, with expectations for further growth [3] - Veracyte maintains a strong balance sheet with over $400 million in cash and has been free cash flow positive since 2023 [3]

Core Insights - Veracyte, Inc. (VCYT) is set to report its fourth-quarter 2025 results on February 25, with expectations of strong performance based on previous earnings surprises [1][9] Financial Performance - The Zacks Consensus Estimate for revenues is $138.7 million, indicating a 16.9% increase from the previous year [2] - The Zacks Consensus Estimate for EPS is 41 cents, reflecting a 13.9% year-over-year growth [2] - Earnings estimates have increased by 2.5% in the last 30 days, suggesting positive sentiment leading up to the earnings report [3] Business Segments - The core testing business is anticipated to show solid revenue growth, driven by strong volumes in Decipher and Afirma tests [4][9] - Decipher Prostate tests delivered approximately 26,700 tests in the third quarter, marking 14 consecutive quarters of over 25% year-over-year volume growth, a trend expected to continue [5] - Test volumes in the high-risk localized segment are also expected to have increased, supported by ongoing research and clinical adoption [6] Product Insights - Product volume in the third quarter was around 2,200 tests, with a year-over-year revenue growth of 4%, a trend expected to persist [7] - However, management has indicated a decline in product gross margin due to a transition to a contract manufacturing model [7][9] Market Position - VCYT has an Earnings ESP of +7.98% and a Zacks Rank of 2 (Buy), indicating a higher likelihood of beating earnings estimates [11] - The company is facing challenges in its biopharma revenues and expects lower product gross margins in the fourth quarter due to restructuring efforts [9][10]